Results 221 to 230 of about 214,460 (382)

Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma ...
Zhe Wang   +3 more
wiley   +1 more source

Bullous Wells' Syndrome: Case Report and Systematic Review. [PDF]

open access: yesJ Clin Med
Ciccarese G   +11 more
europepmc   +1 more source

Distinct Nasal Microbiome Profiles and Prediction Model for Allergic Rhinitis, Nonallergic Rhinitis, and Healthy Children

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
The alpha and beta diversity of the nasal microbiome differed among children with allergic rhinitis (AR), nonallergic rhinitis (NAR), and healthy controls (HCs). Compared to HC, AR had more Escherichia‐Shigella, Negativicoccus, and Campylobacter, while NAR had more Dolosigranulum and fewer Enterobacteriaceae.
Kantima Kanchanapoomi   +6 more
wiley   +1 more source

Development of the Infidelity Tendency Comprehensive (ITCh) Scale

open access: diamond
Raven Kyle Gonzaga   +5 more
openalex   +2 more sources

Itch-related quality of life impact across 3 autoimmune blistering diseases: a retrospective cohort study

open access: hybrid, 2020
Emily Cole   +3 more
openalex   +1 more source

DOES EPIDURAL NALOXONE ALLEVIATE ITCHING FROM INTRATHECAL FENTANYL IN THE LABORING PARTURIENT?  [PDF]

open access: bronze, 2001
Kee-Ryong Choi   +3 more
openalex   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy